CN101437833A - 作为心脏功能调节剂的磷酸酶抑制剂蛋白-1 - Google Patents

作为心脏功能调节剂的磷酸酶抑制剂蛋白-1 Download PDF

Info

Publication number
CN101437833A
CN101437833A CNA2007800120069A CN200780012006A CN101437833A CN 101437833 A CN101437833 A CN 101437833A CN A2007800120069 A CNA2007800120069 A CN A2007800120069A CN 200780012006 A CN200780012006 A CN 200780012006A CN 101437833 A CN101437833 A CN 101437833A
Authority
CN
China
Prior art keywords
nucleic acid
acid molecule
seq
heart
phosphorylating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800120069A
Other languages
English (en)
Chinese (zh)
Inventor
E·克拉尼亚斯
P·罗德里格斯
B·米顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cincinnati
Original Assignee
University of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Cincinnati filed Critical University of Cincinnati
Publication of CN101437833A publication Critical patent/CN101437833A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CNA2007800120069A 2006-02-10 2007-02-09 作为心脏功能调节剂的磷酸酶抑制剂蛋白-1 Pending CN101437833A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77232706P 2006-02-10 2006-02-10
US60/772,327 2006-02-10

Publications (1)

Publication Number Publication Date
CN101437833A true CN101437833A (zh) 2009-05-20

Family

ID=38459499

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800120069A Pending CN101437833A (zh) 2006-02-10 2007-02-09 作为心脏功能调节剂的磷酸酶抑制剂蛋白-1

Country Status (7)

Country Link
US (2) US7989606B2 (enExample)
EP (2) EP1994043A4 (enExample)
JP (2) JP2009525757A (enExample)
CN (1) CN101437833A (enExample)
AU (1) AU2007221470B2 (enExample)
CA (1) CA2638913A1 (enExample)
WO (1) WO2007100465A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006029319A2 (en) 2004-09-09 2006-03-16 The General Hospital Corporation Modulating phosphatase activity in cardiac cells
WO2009090049A1 (en) * 2008-01-14 2009-07-23 European Molecular Biology Laboratory Peptides for the specific binding and regulation of protein targets
ES2634118T3 (es) 2009-02-11 2017-09-26 The University Of North Carolina At Chapel Hill Vectores de virus modificados y métodos para fabricar y utilizar los mismos
CN101942481B (zh) * 2009-04-30 2012-07-25 中南大学 一种针对PKC γ基因RNA干扰的重组慢病毒载体的构建及其应用
CA2810668A1 (en) 2010-09-08 2012-03-15 Halozyme, Inc. Methods for assessing and identifying or evolving conditionally active therapeutic proteins
EP4234571A3 (en) 2011-02-10 2023-09-27 The University of North Carolina at Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
AU2013229786B2 (en) 2012-03-08 2017-06-22 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
WO2014007584A1 (en) * 2012-07-05 2014-01-09 Gwangju Institute Of Science And Technology Decoy peptides inhibiting protein phosphatase 1-mediated dephosphorylation of phospholamban
CA2904396A1 (en) 2013-03-15 2014-09-18 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding aav vectors
WO2016115382A1 (en) 2015-01-14 2016-07-21 The University Of North Carolina At Chapel Hill Methods and compositions for targeted gene transfer
CA2977071A1 (en) 2015-02-20 2016-08-25 Board Of Regents, The University Of Texas System Methods and compositions for attenuated chlamydia as vaccine and vector
EP3831842A1 (en) 2015-09-28 2021-06-09 The University of North Carolina at Chapel Hill Methods and compositions for antibody-evading virus vectors
EP4303225B1 (en) 2017-03-15 2025-11-26 The University of North Carolina at Chapel Hill Polyploid adeno-associated virus vectors and methods of making and using the same
CN112041442A (zh) 2018-02-28 2020-12-04 北卡罗来纳大学查佩尔希尔分校 用于逃避抗体的病毒载体的方法和组合物
EP3773743A1 (en) 2018-04-03 2021-02-17 Stridebio, Inc. Virus vectors for targeting ophthalmic tissues
CN112543766A (zh) 2018-04-03 2021-03-23 斯特里迪比奥公司 抗体逃避性病毒载体
WO2019195449A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
CN113727992A (zh) 2019-03-21 2021-11-30 斯特里迪比奥公司 重组腺相关病毒载体
WO2020219656A1 (en) 2019-04-26 2020-10-29 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding aav2.5 vector
TW202128736A (zh) 2019-10-17 2021-08-01 美商史崔德生物公司 用於治療ｃ型尼曼—匹克病之腺相關病毒載體
TW202227632A (zh) 2020-08-19 2022-07-16 美商史崔德生物公司 用於治療雷特症候群之腺相關病毒載體
WO2022093769A1 (en) 2020-10-28 2022-05-05 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding aav2.5 vector
JP2023547992A (ja) 2020-10-28 2023-11-15 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 二重グリカン結合ａａｖ２．５ベクターのための方法および組成物
TW202242124A (zh) 2021-01-14 2022-11-01 美商史崔德生物公司 靶向ｔ細胞之ａａｖ載體
WO2022221529A1 (en) 2021-04-16 2022-10-20 Asklepios Biopharmaceutical, Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
WO2023150687A1 (en) 2022-02-04 2023-08-10 Ginkgo Bioworks, Inc. Recombinant adeno-associated virus vectors, and methods of use thereof
WO2024124019A2 (en) 2022-12-07 2024-06-13 Ginkgo Bioworks, Inc. Aav vectors targeting hematopoietic stem cells

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5753258A (en) 1990-10-19 1998-05-19 University Of Florida Artificial viral envelopes
US5252348A (en) 1990-10-19 1993-10-12 Univ. Of Florida Research Foundation, Inc. Artificial viral envelopes
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
CA2203809C (en) 1994-10-28 2008-06-03 James M. Wilson Recombinant adenovirus and methods of use thereof
EP0821740A1 (en) 1995-04-20 1998-02-04 Chiron Corporation High efficiency ex vivo transduction of hematopoietic stem cells by recombinant retroviral preparations
WO1997015679A1 (en) 1995-10-27 1997-05-01 The Trustees Of The University Of Pennsylvania Recombinant viruses containing mobile genetic elements and methods of use in gene therapy
CA2263705C (en) 1996-08-19 2007-12-04 Nancy Smyth-Templeton Novel sandwich liposome complexes comprising a biologically active agent
AU5153498A (en) * 1996-10-23 1998-05-15 Duke University Human phosphatase inhibitor-1 gene and methods of screening for non-insulin dependent diabetes mellitus
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
AU6814901A (en) 2000-06-01 2001-12-11 Univ North Carolina Methods and compounds for controlled release of recombinant parvovirus vectors
ES2256265T3 (es) 2000-06-01 2006-07-16 University Of North Carolina At Chapel Hill Vectores de parvovirus duplicados.
WO2002022177A2 (en) 2000-09-11 2002-03-21 The Regents Of The University Of California High efficiency cardiac gene transfer
AU2002249947A1 (en) 2001-01-15 2002-07-30 Henry Ford Health System Inhibition of protein-phosphatases for the treatment of heart failure
US20020159978A1 (en) * 2001-02-06 2002-10-31 James Allen Muscle-directed gene transfer by use of recombinant AAV-1 and AAV-6 virions
MXPA05005653A (es) * 2002-11-27 2005-11-23 Artesian Therapeutics Inc Determinacion y seleccion terapeutica de genes de insuficiencia cardiaca.
WO2005027629A2 (en) 2003-09-19 2005-03-31 Children's Hospital Medical Center Regulation of cardiac contractility and heart failure propensity
WO2006029319A2 (en) * 2004-09-09 2006-03-16 The General Hospital Corporation Modulating phosphatase activity in cardiac cells

Also Published As

Publication number Publication date
EP2441770A1 (en) 2012-04-18
JP2009525757A (ja) 2009-07-16
US8524683B2 (en) 2013-09-03
US20090203596A1 (en) 2009-08-13
US7989606B2 (en) 2011-08-02
US20120053125A1 (en) 2012-03-01
CA2638913A1 (en) 2007-09-07
EP1994043A2 (en) 2008-11-26
JP2013027398A (ja) 2013-02-07
WO2007100465A2 (en) 2007-09-07
EP1994043A4 (en) 2009-05-20
WO2007100465A3 (en) 2008-07-31
AU2007221470A1 (en) 2007-09-07
AU2007221470B2 (en) 2013-02-14

Similar Documents

Publication Publication Date Title
US7989606B2 (en) Phosphatase inhibitor protein-1 as a regulator of cardiac function
US5639661A (en) Genes and proteins for treating cystic fibrosis
CA2340328C (en) Stable hypoxia inducible factor-1 alpha and method of use
PT2040728E (pt) Fkbp-l e seus usos como inibidores de angiogénese
JP2008037870A (ja) 心臓病及び心不全の治療のためのホスホランバン活性の阻害方法
US7588756B1 (en) Treatment of cardiac power failure
WO2001093897A9 (en) Angiostatin and endostatin binding proteins and methods of use
KR20240130829A (ko) 허혈/재관류 손상
CN101506226A (zh) 改良的色素上皮衍生因子变体及其用途
WO2017029206A1 (en) Use of k2p potassium channel for altering the electrophysiology of the heart
KR20190008511A (ko) cMLCK 유전자 이식
US20230295658A1 (en) Compositions and methods for in vivo gene transfer
HK1129392A (en) Phosphatase inhibitor protein-1 as a regulator of cardiac function
HUT74413A (en) A novel tumor suppressor gene
US20190134223A1 (en) Methods and compositions for treating heart failure
CA2485138C (en) Androgen-regulated pmepa1 gene and methods of using the same to inhibit cancer cell growth
KR102267495B1 (ko) 미토콘드리아 타겟팅용 폴리펩타이드 및 그 용도
US7309606B2 (en) Methods and compositions for treating hypercholesterolemia
JP2006524712A (ja) カテプシンの阻害のための方法および組成物
EP4531887A1 (en) S100a1 protein for use in treating and preventing infarct extension
CN118749000A (zh) 用于治疗核纤层蛋白病的lmna基因表达
JP2002085059A (ja) 新規なｔｓｐ１ドメイン含有ポリペプチド

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1129392

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090520

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1129392

Country of ref document: HK